Moody’s Corporation -- 7.8/10 -- $440.79

Moody’s is one-third of the global credit ratings triopoly alongside S&P Global and Fitch, holding approximately 34% of the market. The NRSRO designation creates a regulatory moat that makes ratings effectively mandatory for investment-grade and most high-yield debt issuance. Barriers to entry are insurmountable -- no new meaningful competitor has emerged in decades. This is one of the strongest moats in all of financial services.

The business operates in two segments. Moody’s Investors Service (MIS) is the ratings toll-road, generating $4.3B in FY2025 revenue with segment margins of 63.6%. Moody’s Analytics (MA) has been transformed into a recurring-revenue SaaS and data platform -- 97% recurring revenue (up from 95% in FY2024), with total ARR of $3.5B. Management has pruned the MA portfolio (divesting Learning Solutions and Regulatory Reporting) to concentrate on higher-growth, higher-margin businesses like Decision Solutions (KYC, Insurance, Banking).

Private credit is the most exciting structural growth driver. Private credit across all asset classes grew 40% in Q4 2025, with nearly 400 mandates and one-third of FIG first-time mandates coming from private credit (BDCs, asset managers, private credit funds). The MSCI partnership for EDFX quantitative credit risk scores extends the opportunity from GPs to LPs and investors. This is a multi-year TAM expansion story.

GenAI positions Moody’s as the trusted context layer for financial AI. The proprietary data estate (entity resolution, Orbis ownership data) is the critical infrastructure for AI-driven financial decision-making. GenAI-enabled navigators are live across 8 MA solutions, the AI screening agent reduces KYC false positives, and customers who buy at least one AI solution grow at 2x the rate of others. FY2025 was a strong year: revenue +9%, EPS +20%, margin expansion of 300bps, and FCF of $2.6B (33% of revenue).

MCO receives a composite score of 7.8/10, reflecting a high-quality compounder with one of the strongest moats in financial services, trading at a reasonable but not compelling valuation.

Bull case: The ratings triopoly is unassailable -- ~34% global share, NRSRO regulatory moat, and ratings effectively mandatory for debt issuance. FCF generation is excellent ($2.6B in FY2025, guided to $2.8-3.0B in FY2026). Private credit is a structural TAM expansion (~400 mandates, 40% Q4 growth, MSCI partnership), and GenAI positions the proprietary data estate as critical infrastructure for financial AI. MA transformation to 97% recurring revenue with expanding margins (29.7% to 35.7% in 8 quarters) provides earnings visibility. At ~27x NTM P/E (below the 5-year average of 30-32x) with 12% EPS growth guided for FY2026, the risk-reward is reasonable for a franchise of this quality.

Bear case: MIS cyclicality is real -- FY2022 demonstrated a 28% revenue decline when issuance dried up. MA ARR growth has decelerated from double-digits to 7%, and GenAI monetization has not yet translated into visible ARR acceleration. At ~27x NTM P/E, MCO is not cheap in absolute terms, and a re-rating to 30x+ requires sustained execution on both MIS growth and MA margin expansion. Tariff-related macro uncertainty could compress issuance volumes near-term.

Key differentiator: Unlike pure-play data companies, Moody’s has a dual-engine model where the MIS toll-road provides cyclical upside while MA recurring revenue provides stability. The combination creates a compounder with both growth and defensibility.

Key catalysts and monitoring points:

• FY2026 quarterly cadence: Management guided issuance front-loaded with revenue growth in every quarter. MIS margin guide of ~65% exceeds medium-term target of low-60s. Track whether Q2 2026 MIS revenue softness (guided down mid-single digits on tariff uncertainty) proves temporary.
• Private credit scaling: The 40% Q4 growth and ~400 mandates are leading indicators. Watch first-time mandate growth (up 20% YoY in Q1 2025) and MSCI EDFX partnership traction as the opportunity extends from GPs to LPs.
• MA ARR reacceleration: Total MA ARR growth has moderated to 7%. Decision Solutions ARR at 9% is the strongest sub-segment. Watch whether GenAI-enabled solutions drive visible ARR acceleration -- management points to leading indicators (largest customers growing 2x, AI cohort growing 2x) but hard revenue proof is needed.
• MA margin trajectory: Margins expanded from 29.7% to 35.7% in 8 quarters. Guided 34-35% for FY2026 (conservative vs. recent trajectory). Portfolio pruning and GenAI productivity should sustain 100-200bps annual expansion. A path to 40%+ would be a meaningful re-rating catalyst.
• Issuance cycle dynamics: Refining wall, private credit growth, and infrastructure/data center financing provide structural underpinning beyond traditional cycles. A severe credit crunch remains the key downside risk.
• Capital return execution: FY2026 guide calls for ~$2B buybacks and 10% dividend increase, returning 90%+ of FCF to shareholders.

For the full analysis, see the Business Model, Financials, and Valuation pages.

Concerns, Catalysts & Risks -- full analysis

Hold at current levels -- Moody’s is a core-quality compounder with an unassailable moat, but the valuation requires patience rather than urgency. At $440.79 (19% below the 52-week high of $546.88), the stock trades at ~27x NTM P/E on FY2026E midpoint of $16.70. This is below the 5-year average of 30-32x, suggesting the market has already de-rated the stock for near-term uncertainty.

The setup for FY2026 is constructive. Management guided high-single-digit revenue growth, 52-53% adj operating margins (+150bps), and $16.40-$17.00 adj EPS (+10-14%). FCF is guided to $2.8-3.0B, implying a ~3.7% FCF yield. Private credit and GenAI provide multi-year secular growth vectors that are not yet fully priced. The analyst consensus PT of ~$551 implies ~25% upside.

Risk management: The main risks are MIS issuance cyclicality (proven in 2022), MA ARR deceleration, and the premium absolute valuation. A pullback to the $380-$400 range (~23-24x FY2026E) on macro or issuance weakness would upgrade the recommendation to BUY. For existing holders, the franchise quality and secular growth vectors support continued ownership. For new positions, the 19% discount to ATH and below-average multiple provide a reasonable entry, but this is a hold-and-compound story rather than a near-term catalyst play.